20.500.12556/DiRROS-27802 The efficacy of first-line pembrolizumab monotherapy in patients with metastatic NSCLC aged ≥70 years with high PD-L1 (TPS ≥50%) expression: a multicenter real-world study The efficacy of first-line pembrolizumab monotherapy in patients with metastatic NSCLC aged ≥70 years with high PD-L1 (TPS ≥50%) expression This real-world study assessed the effectiveness of first-line pembrolizumab monotherapy in patients with metastatic non-oncogene-addicted NSCLC and PD-L1 TPS ≥50%, comparing those aged ≥70 years to younger patients. Results showed no significant differences in outcomes—objective response rate, time on treatment (ToT), and overall survival (OS)—between the two age groups. In older patients, a history of smoking and good performance status (ECOG PS 0–1) were associated with better outcomes. Poor ECOG PS (≥2) was linked to shorter ToT and OS, regardless of age. Older patients were less likely to receive second-line therapy due to comorbidities and functional decline. These findings highlight the importance of performance status over chronological age in predicting benefit from immunotherapy and support pembrolizumab monotherapy as an effective firstline option for older patients with good functional status. NSCLC PD-L1 real-world data NSCLC PD-L1 podatki iz resničnega življenja true false true Angleški jezik Slovenski jezik © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Neznano 2026-02-25 10:50:59 2026-02-25 10:50:59 2026-02-26 03:55:12 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Urška Jančič; Opis vira z dne 30. 6. 2025; 13 str. issue 13, [article no.] 2190 Vol. 17 2025 0000-00-00 Zaloznikova Objavljeno apc 2025-04-27 2025-04-23 2025-01-01 616.24-006.44-053.9:615.277 2072-6694 10.3390/cancers17132190 240793091 https://www.mdpi.com/2072-6694/17/13/2190 1 7dc3cf3e-122f-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40880 RAZ_Markovic_Filip_2025.pdf RAZ_Markovic_Filip_2025.pdf 1 470E90E5A91A2AAB2CFCF617675BAF6A 7787a8a026d835b1e2e40139cf7d0e12121deeb75741b8699f310adb7ca067a4 c689ec40-122f-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40881 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0